Affimed Stock Price, News & Analysis

Affimed N.V. (Nasdaq: AFMD) showcased promising preclinical data for its bispecific innate cell engager, AFM28, targeting CD123 in treating relapsed/refractory acute myeloid leukemia (AML) at the EHA Annual Meeting. AFM28 demonstrated potent anti-tumor activity against CD123-positive cells, even at low expression levels, while sparing healthy cells. In vivo studies indicated strong anti-tumor efficacy and a favorable safety profile. A first-in-human phase 1 clinical trial is set to commence in the second half of 2022, aiming to assess AFM28’s safety and efficacy as a monotherapy and in combination with NK cell therapies.

Affimed N.V. (Nasdaq: AFMD) reported its first quarter 2022 financial results and clinical updates. The REDIRECT study for AFM13 monotherapy completed enrollment, with topline data expected in Q4 2022. At AACR 2022, AFM13 showed a 100% objective response rate and a rise in complete responses. The cash position is strong, with €257.5 million expected to support operations into mid-2024. However, net loss for Q1 2022 was €16.7 million, down from a profit a year ago, while R&D expenses surged by 61% to €18.4 million, indicating increased investment in their product pipeline.

Affimed (Nasdaq: AFMD) announced three clinical trial designs for its AFM24 innate cell engager (ICE®), showcased at the ASCO Annual Meeting from June 3-7, 2022. The trials include AFM24 monotherapy and combinations with atezolizumab and SNK01 autologous NK cells, targeting advanced EGFR-expressing solid tumors. AFM24 aims to activate the innate immune system, showing a well-managed safety profile and established recommended phase 2 dose (RP2D) of 480 mg. These innovative approaches represent potential advancements in treatment for patients resistant to current therapies.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announced that CEO Dr. Adi Hoess will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 1:00 PM EDT. The presentation will focus on Affimed's commitment to empowering the innate immune system to fight cancer. A live webcast will be available on Affimed's website, with a replay accessible for 30 days post-event. For inquiries about the conference or to schedule meetings, interested parties can contact Jefferies or reach out to Alex Fudukidis.

Affimed N.V. (Nasdaq: AFMD) announced that its 2022 Annual General Meeting of Shareholders will take place on June 22, 2022, at 09:00 a.m. CET in Amsterdam. The meeting aims to discuss company performance and future strategies. Shareholders can access the notice and agenda on Affimed's website or through the SEC's site. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to develop innovative therapies targeting various cancers. The company is committed to enhancing patients' innate ability to combat cancer.

Affimed N.V. (Nasdaq: AFMD) announced it will release its Q1 2022 financial results and provide a corporate update on June 1, 2022. A conference call will take place at 8:30 a.m. EDT, available via phone and webcast. The call can be accessed by dialing +1 (409) 220-9054 for U.S. participants and +44 (0) 8000 323836 for international callers, using conference ID 4440407. Affimed focuses on immuno-oncology and utilizes its proprietary ROCK® platform to develop innovative cancer therapies.

Affimed N.V. (Nasdaq: AFMD) presented new data on AFM24 and AFM28 at the NK2022 conference, highlighting their potential in cancer treatment. The AFM24 data showed its efficacy as a CD16A/EGFR-targeting bispecific innate cell engager, stimulating anti-cancer immunity in patients with EGFR-expressing tumors. Meanwhile, AFM28 demonstrated anti-leukemic effects when combined with NK cells, suggesting it could offer an off-the-shelf therapy for AML and MDS patients. Both compounds are currently undergoing phase 1/2a clinical studies.

Affimed N.V. (Nasdaq: AFMD) announced the upcoming first-in-human phase 1 study of its bispecific innate cell engager AFM28, targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). This innovative therapy showed promising results in preclinical studies, effectively destroying CD123-positive tumor cells while sparing healthy cells. Toxicology models indicated low risks of side effects such as cytokine release syndrome. The study is set to begin in the second half of 2022, with a poster presentation scheduled at the EHA Annual Meeting in June 2022.

Affimed N.V. (Nasdaq: AFMD) announced that the American Society of Clinical Oncology (ASCO) has removed the oral presentation of the AFM13-104 trial from its conference program. This decision was due to ASCO's embargo policy, following the recent data presentation at the AACR Annual Meeting on April 10, 2022. Affimed clarified that this removal is unrelated to the ongoing trial's status or results. The company is collaborating with The University of Texas MD Anderson Cancer Center to submit additional data on AFM13-104 to a future scientific forum.